

DuPont de Nemours, Inc. ("DuPont" or the "Company")
Reconciliation of non-GAAP financial measures and other supplemental information

Effective in the fourth quarter of 2025, following the separation of the Electronics business on November 1, 2025, the Company made changes to its management and reporting structure (the "Q4 2025 Segment Realignment") creating two new reportable segments: Healthcare & Water Technologies and Diversified Industrials.

The Company is providing unaudited revised supplemental financial information for the years ended December 31, 2024, for the nine months ended September 30, 2025, as well as the three month periods ended March 31, 2025 and 2024, June 30, 2025 and 2024, September 30, 2025 and 2024, and December 31, 2024 that reflects the Electronics business and the Aramids Divestiture as discontinued operations. The Company is also providing select supplemental unaudited segment information for the periods above reflecting the Q4 2025 Segment Realignment. This information reflects preliminary estimates and is subject to change and will be finalized in the Company's 2025 Form 10-K.

Unless otherwise indicated, all financial metrics presented reflect continuing operations only.

This communication includes information that does not conform to accounting principles generally accepted in the United States of America ("U.S. GAAP") and are considered non-GAAP measures. Management uses these measures internally for planning, forecasting and evaluating the performance of the Company, including allocating resources. DuPont's management believes these non-GAAP financial measures are useful to investors because they provide additional information related to the ongoing performance of DuPont to offer a more meaningful comparison related to future results of operations. These non-GAAP financial measures supplement disclosures prepared in accordance with U.S. GAAP, and should not be viewed as an alternative to U.S. GAAP. Furthermore, such non-GAAP measures may not be consistent with similar measures provided or used by other companies. Reconciliations for these non-GAAP measures to U.S. GAAP are provided in the following tables. Non-GAAP measures included in this communication are defined below. The Company has not provided forward-looking U.S. GAAP financial measures or a reconciliation of forward-looking non-GAAP financial measures to the most comparable U.S. GAAP financial measures on a forward-looking basis because the Company is unable to predict with reasonable certainty the ultimate outcome of certain future events. These events include, among others, the impact of portfolio changes, including asset sales, mergers, acquisitions, and divestitures; contingent liabilities related to litigation, environmental and indemnifications matters; impairments and discrete tax items. These items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP results for the guidance period.

Indirect costs, such as those related to corporate and shared service functions previously allocated to the Aramids Divestiture or Electronics business, do not meet the criteria for discontinued operations and were reported within continuing operations in the respective prior periods. A portion of these historical indirect costs include costs related to activities the Company is or will be undertaking on behalf of the Aramids or Electronics business and for which it will or are reimbursed ("Future Reimbursable Indirect Costs"). Future Reimbursable Indirect Costs are reported within continuing operations but are excluded from operating EBITDA as defined below. The remaining portion of these indirect costs is not subject to future reimbursement ("Stranded Costs"). Stranded Costs are reported within continuing operations in Corporate & Other and are included within Operating EBITDA.

Adjusted Earnings is defined as income from continuing operations excluding the after-tax impact of significant items, after-tax impact of amortization expense of intangibles, the after-tax impact of non-operating pension / other post employment benefits ("OPEB") credits / costs, Future Reimbursable Indirect Costs, and corporate remediation costs associated with divested businesses. Adjusted Earnings is the numerator used in the calculation of Adjusted EPS, as well as the denominator in Adjusted Free Cash Flow Conversion. Subsequent to the separation of the Electronics business and beginning with the fourth quarter of 2025, the Company updated its Adjusted Earnings definition to remove remediation costs associated with divested businesses as it believes the update reflects a more accurate measure of the ongoing performance of the Company. Remediation costs associated with divested businesses include environmental remediation costs including certain investigative, remediation, and restoration activities at sites where the Company once conducted operations or at sites where waste generated by the Company was disposed.

Adjusted EPS is defined as Adjusted Earnings per common share - diluted. Management estimates amortization expense in 2025 associated with intangibles to be about \$290 million on a pre-tax basis, or approximately \$0.50 per share.

The Company's measure of profit/loss for segment reporting purposes is Operating EBITDA as this is the manner in which the Company's chief operating decision maker ("CODM") assesses performance and allocates resources. The Company defines Operating EBITDA as earnings (i.e., "Income from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / OPEB benefits / charges, and foreign exchange gains / losses, excluding Future Reimbursable Indirect Costs and corporate remediation costs associated with divested businesses, and adjusted for significant items. Reconciliations of these measures are provided on the following pages. Subsequent to the separation of the Electronics business and beginning with the fourth quarter of 2025, the Company updated its Operating EBITDA definition to remove corporate remediation costs associated with divested businesses as it believes the update to Operating EBITDA reflects a more accurate measure of the ongoing performance of the Company.

Operating EBITDA Margin is defined as Operating EBITDA divided by Net Sales.

Significant items are items that arise outside the ordinary course of business for the Company, and beginning in the first quarter 2025, includes items for nonconsolidated affiliates, that the Company's management believes may cause misinterpretation of underlying business and investment performance, both historical and future, based on a combination of some or all of the item's size, unusual nature and infrequent occurrence. Management classifies as significant items certain costs and expenses associated with integration and separation activities related to transformational acquisitions and divestitures as they are considered unrelated to ongoing business performance. Management believes the update to the definition of significant items to include those related to nonconsolidated affiliates reflects a more accurate measure of the ongoing performance of the investment.

DuPont de Nemours, Inc.

Net Sales (Unaudited)

<i>In millions</i>	YTD 2025	3Q25	2Q25	1Q25	FY 2024	4Q24	3Q24	2Q24	1Q24
Net Sales	\$ 5,156	\$ 1,795	\$ 1,749	\$ 1,612	\$ 6,719	\$ 1,689	\$ 1,714	\$ 1,717	\$ 1,599

Selected Non-GAAP Calculation of Operating EBITDA (Unaudited)

<i>In millions</i>	YTD 2025	3Q25	2Q25	1Q25	FY 2024	4Q24	3Q24	2Q24	1Q24
Income (loss) from continuing operations, net of tax (GAAP)	\$ 206	\$ 102	\$ 24	\$ 80	\$ (96)	\$ (291)	\$ 221	\$ (28)	\$ 2
+ Provision for (benefit from) income taxes on continuing operations	60	(11)	54	17	213	92	66	29	26
Income (loss) from continuing operations before income taxes	\$ 266	\$ 91	\$ 78	\$ 97	\$ 117	\$ (199)	\$ 287	\$ 1	\$ 28
+ Depreciation and amortization	488	162	166	160	635	163	163	158	151
- Interest income ¹	52	17	18	17	74	19	14	21	20
+ Interest expense ²	250	84	84	82	365	84	86	99	96
- Non-operating pension/OPEB benefit credits (costs)	2	-	-	2	9	2	2	-	5
- Foreign exchange (losses) gains, net	(29)	(12)	(14)	(3)	(3)	16	(14)	(4)	(1)
+ Future reimbursable indirect costs	75	25	25	25	100	25	25	25	25
+ Remediation costs associated with divested businesses	8	3	2	3	14	3	3	4	4
- Adjustments for significant items (charge) benefit	(157)	(76)	(72)	(9)	(380)	(356)	147	(130)	(41)
Operating EBITDA (non-GAAP)	\$ 1,219	\$ 436	\$ 423	\$ 360	\$ 1,531	\$ 395	\$ 415	\$ 400	\$ 321

1. Excludes accrued interest income earned on employee retention credits and employee retention credits and interest income earned on cash held in escrow associated with the Qnity financing. Refer to details of significant items on the following page.
2. Excludes interest rate swap basis amortization. Refer to details of significant items on the following page.

GAAP Income from Continuing Operations Margin

<i>In millions</i>	YTD 2025	3Q25	2Q25	1Q25	FY 2024	4Q24	3Q24	2Q24	1Q24
Income (loss) from continuing operations margin	4.0%	5.7%	1.4%	5.0%	(1.4)%	(16.4)%	12.8%	(1.6)%	(0.6)%

Operating EBITDA Margin

<i>In millions</i>	YTD 2025	3Q25	2Q25	1Q25	FY 2024	4Q24	3Q24	2Q24	1Q24
Total operating EBITDA margin (non-GAAP) ¹	23.6%	24.3%	24.2%	22.3%	22.8%	23.4%	24.2%	23.3%	20.1%

1. Operating EBITDA Margin is Operating EBITDA as a percentage of net sales.

DuPont de Nemours, Inc.

Pretax Significant Items (Unaudited)

<i>In millions</i>	YTD 2025	3Q25	2Q25	1Q25	FY 2024	4Q24	3Q24	2Q24	1Q24
Acquisition, integration and separation costs ²	\$ (167)	\$ (62)	\$ (55)	\$ (50)	\$ (90)	\$ (59)	\$ (24)	\$ (4)	\$ (3)
Restructuring and asset-related charges - net ³	(57)	(18)	-	(39)	(57)	(9)	(15)	(13)	(20)
Income tax related item ⁴	-	-	-	-	7	-	-	-	7
Inventory write-offs ⁵	-	-	-	-	(25)	2	(2)	-	(25)
Loss on debt extinguishment ⁶	-	-	-	-	(74)	-	-	(74)	-
Interest rate swap mark-to-market gain (loss) ⁷	46	(4)	(27)	77	(139)	(290)	190	(39)	-
Qnity Financing ⁸	9	9	-	-	-	-	-	-	-
Other benefits (credits), net ⁹	12	(1)	10	3	(2)	-	(2)	-	-
Total pretax significant items (charge) benefit	\$ (157)	\$ (76)	\$ (72)	\$ (9)	\$ (380)	\$ (356)	\$ 147	\$ (130)	\$ (41)

Significant Items, net of tax (Unaudited)

<i>In millions</i>	YTD 2025	3Q25	2Q25	1Q25	FY 2024	4Q24	3Q24	2Q24	1Q24
Total significant items (charge) benefit, net of tax	\$ (78)	\$ (5)	\$ (76)	\$ 3	\$ (400)	\$ (380)	\$ 109	\$ (99)	\$ (30)

Significant Items Earnings Per Share (Unaudited)

<i>In millions</i>	YTD 2025 ¹	3Q25	2Q25	1Q25	FY 2024 ¹	4Q24	3Q24	2Q24	1Q24
Total significant items (charge) benefit - diluted	\$ (0.19)	\$ (0.01)	\$ (0.19)	\$ 0.01	\$ (0.95)	\$ (0.90)	\$ 0.26	\$ (0.24)	\$ (0.07)

1. Earnings (Loss) per share amounts from continuing operations - diluted for the year may not equal the sum of the quarterly (loss) earnings per common share from continuing operations - diluted amounts due to the change in average share calculations.

2. Acquisition, integration and separation costs primarily related to the Previously Intended Business Separations, the Electronics Separation, the acquisitions of Donatelle Plastics and Spectrum Plastics Group, and the sale of divested business units.

3. Includes restructuring actions and asset related charges.

4. Reflects the impact of an international tax audit in Q1 2024.

5. Reflects net raw material inventory write-offs recorded in "Cost of Sales" in connection with restructuring actions related to plant line closures.

6. Reflects the loss on extinguishment of debt related to the partial redemption of the 2038 Notes.

7. Includes the mark-to-market gain (loss) related to the 2022 Swaps and 2024 Swaps, net interest settlement loss and basis amortization related to the 2022 Swaps.

8. Includes interest income earned on cash held in escrow (\$9 million pre-tax) associated with the Qnity notes.

9. Other benefits (credits), net includes the following items:

- FY 2025 includes legal costs associated with pending intellectual property matter (Q2 2025: \$5 million pre-tax cost, Q3 2025: \$9 million pre-tax cost), benefits related to an adjustment of the Donatelle contingent earn-out liability (Q2 2025: \$12 million pre-tax benefit, Q3 2025: \$7 million pre-tax benefit), and Employee Retention Credits pursuant to the Coronavirus Aid, Relief, and Economic Security ("CARES") Act (Q1 2025: \$3 million pre-tax benefit, Q2 2025: \$3 million pre-tax benefit).

- Q3 2024 reflects amortization of an inventory step-up adjustment related to the Donatelle Plastics acquisition (Q3 2024: \$2 million pre-tax cost).

DuPont de Nemours, Inc.

Adjusted EPS

Pretax Non-GAAP Adjustments to Net Income (Unaudited)

<i>In millions</i>	YTD 2025	3Q25	2Q25	1Q25	FY 2024	4Q24	3Q24	2Q24	1Q24
Income (loss) from continuing operations before income taxes (GAAP)	\$ 266	\$ 91	\$ 78	\$ 97	\$ 117	\$ (199)	\$ 287	\$ 1	\$ 28
Less: Significant items (charge) benefit, before tax ¹	(157)	(76)	(72)	(9)	(380)	(356)	147	(130)	(41)
Less: Amortization of intangibles, before tax ¹	(220)	(71)	(74)	(75)	(294)	(76)	(75)	(73)	(70)
Less: Non-op pension / OPEB benefit credits (costs), before tax ¹	2	-	-	2	9	2	2	-	5
Less: Future reimbursable indirect costs, before tax ¹	(75)	(25)	(25)	(25)	(100)	(25)	(25)	(25)	(25)
Less: Remediation costs associated with divested businesses ¹	(8)	(3)	(2)	(3)	(14)	(3)	(3)	(4)	(4)
Adjusted earnings, before tax (non-GAAP)	\$ 724	\$ 266	\$ 251	\$ 207	\$ 896	\$ 259	\$ 241	\$ 233	\$ 163

1. Impact on income (loss) from continuing operations before income taxes.

Non-GAAP Adjustments to Net Income (Unaudited)

<i>In millions</i>	YTD 2025	3Q25	2Q25	1Q25	FY 2024	4Q24	3Q24	2Q24	1Q24
Net income (loss) from continuing operations available to DuPont common stockholders (GAAP)	\$ 199	\$ 98	\$ 23	\$ 78	\$ (98)	\$ (294)	\$ 221	\$ (26)	\$ 1
Less: Significant items (charge) benefit, net of tax ¹	(78)	(5)	(76)	3	(400)	(380)	109	(99)	(30)
Less: Amortization of intangibles, net of tax ¹	(172)	(55)	(58)	(59)	(231)	(60)	(59)	(57)	(55)
Less: Non-op pension / OPEB benefit credits (costs), net of tax ¹	2	-	-	2	7	2	1	-	4
Less: Future reimbursable indirect costs, net of tax ¹	(58)	(19)	(19)	(20)	(77)	(19)	(19)	(20)	(19)
Less: Remediation costs associated with divested businesses ¹	(6)	(3)	(1)	(2)	(10)	(2)	(2)	(3)	(3)
Adjusted earnings, net of tax (non-GAAP)	\$ 511	\$ 180	\$ 177	\$ 154	\$ 613	\$ 165	\$ 191	\$ 153	\$ 104

1. Impact on income (loss) from continuing operations available to DuPont common stockholders, net of tax. The income tax effect for each adjustment was calculated based on the statutory tax rate for the jurisdiction(s) in which the adjustment was taxable or deductible.

Non-GAAP Adjustments to Earnings Per Share (Unaudited)

<i>In millions</i>	YTD 2025 ¹	3Q25	2Q25	1Q25	FY 2024 ¹	4Q24	3Q24	2Q24	1Q24
Earnings (loss) per common share from continuing operations - diluted (GAAP)	\$ 0.48	\$ 0.23	\$ 0.05	\$ 0.19	\$ (0.23)	\$ (0.70)	\$ 0.53	\$ (0.06)	\$ -
Less: Significant items (charge) benefit - diluted ²	(0.19)	(0.01)	(0.19)	0.01	(0.95)	(0.90)	0.26	(0.24)	(0.07)
Less: Amortization of intangibles - diluted ²	(0.41)	(0.13)	(0.14)	(0.14)	(0.55)	(0.14)	(0.14)	(0.14)	(0.13)
Less: Non-op pension / OPEB benefit credits (costs) - diluted ²	0.01	-	-	-	0.02	-	-	-	0.01
Less: Future reimbursable indirect costs - diluted ²	(0.14)	(0.05)	(0.05)	(0.04)	(0.18)	(0.04)	(0.04)	(0.05)	(0.05)
Less: Remediation costs associated with divested businesses ²	(0.01)	(0.01)	-	-	(0.02)	(0.01)	(0.01)	-	-
Adjusted earnings per common share from continuing operations - diluted (non-GAAP)	\$ 1.22	\$ 0.43	\$ 0.43	\$ 0.36	\$ 1.45	\$ 0.39	\$ 0.46	\$ 0.37	\$ 0.24

1. Earnings (loss) per share amounts from continuing operations - diluted for the year may not equal the sum of the quarterly earnings (loss) per common share from continuing operations - diluted amounts due to the change in average share calculations.

2. Impact on earnings per common share from continuing operations - diluted.

DuPont de Nemours, Inc.
Supplemental Information - Selected Segment Information (Unaudited)

Net Trade Revenue by Segment and Business or Major Product Line

<i>In millions</i>	YTD 2025	3Q25	2Q25	1Q25	FY 2024	4Q24	3Q24	2Q24	1Q24	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Healthcare Technologies ¹	\$ 1,321	\$ 458	\$ 444	\$ 419	\$ 1,568	\$ 412	\$ 406	\$ 391	\$ 359	\$ 1,459	\$ 1,342	\$ 1,302	\$ 1,289	\$ 1,067
Water Technologies ¹	1,091	374	373	344	1,408	378	363	353	314	1,460	1,493	1,370	1,276	1,117
Healthcare & Water Technologies¹	\$ 2,412	\$ 832	\$ 817	\$ 763	\$ 2,976	\$ 790	\$ 769	\$ 744	\$ 673	\$ 2,919	\$ 2,835	\$ 2,672	\$ 2,565	\$ 2,184
Building Technologies ¹	\$ 1,224	\$ 430	\$ 419	\$ 375	\$ 1,703	\$ 419	\$ 436	\$ 443	\$ 405	\$ 1,715	\$ 1,894	\$ 1,712	\$ 1,508	\$ 1,611
Industrial Technologies ¹	1,520	533	513	474	2,040	480	509	530	521	1,980	3,531	3,777	3,416	4,586
Diversified Industrials¹	\$ 2,744	\$ 963	\$ 932	\$ 849	\$ 3,743	\$ 899	\$ 945	\$ 973	\$ 926	\$ 3,695	\$ 5,425	\$ 5,489	\$ 4,924	\$ 6,197
Total	\$ 5,156	\$ 1,795	\$ 1,749	\$ 1,612	\$ 6,719	\$ 1,689	\$ 1,714	\$ 1,717	\$ 1,599	\$ 6,614	\$ 8,260	\$ 8,161	\$ 7,489	\$ 8,381

1. Effective in the fourth quarter of 2025, as a result of the Electronics Separation, the Company realigned its management and reporting structure. This realignment resulted in a change in reportable segments in the fourth quarter of 2025 which changed the manner in which the Company reports financial results by segment. The information presented above has been recast for all periods presented to reflect the new two segment reporting structure.

DuPont de Nemours, Inc.
Segment Information (Unaudited)

Net Sales

<i>In millions</i>	YTD 2025	3Q25	2Q25	1Q25	FY 2024	4Q24	3Q24	2Q24	1Q24
Healthcare & Water Technologies	\$ 2,412	\$ 832	\$ 817	\$ 763	\$ 2,976	\$ 790	\$ 769	\$ 744	\$ 673
Diversified Industrials	2,744	963	932	849	3,743	899	945	973	926
Total net sales by segment	\$ 5,156	\$ 1,795	\$ 1,749	\$ 1,612	\$ 6,719	\$ 1,689	\$ 1,714	\$ 1,717	\$ 1,599

Operating EBITDA

<i>In millions</i>	YTD 2025	3Q25	2Q25	1Q25	FY 2024	4Q24	3Q24	2Q24	1Q24
Healthcare & Water Technologies	\$ 717	\$ 246	\$ 248	\$ 223	\$ 844	\$ 246	\$ 230	\$ 205	\$ 163
Diversified Industrials	603	219	199	185	839	193	215	217	214
Corporate	(101)	(29)	(24)	(48)	(152)	(44)	(30)	(22)	(56)
Total operating EBITDA (non-GAAP)	\$ 1,219	\$ 436	\$ 423	\$ 360	\$ 1,531	\$ 395	\$ 415	\$ 400	\$ 321

Operating EBITDA Margin

<i>In millions</i>	YTD 2025	3Q25	2Q25	1Q25	FY 2024	4Q24	3Q24	2Q24	1Q24
Healthcare & Water Technologies	29.7%	29.6%	30.4%	29.2%	28.4%	31.1%	29.9%	27.6%	24.2%
Diversified Industrials	22.0%	22.7%	21.4%	21.8%	22.4%	21.5%	22.8%	22.3%	23.1%
Total operating EBITDA margin (non-GAAP)^{1,2}	23.6%	24.3%	24.2%	22.3%	22.8%	23.4%	24.2%	23.3%	20.1%

1. Operating EBITDA Margin is Operating EBITDA as a percentage of net sales.

2. Operating EBITDA Margin %s for Corporate are not presented separately above as they are not meaningful; however, the results of Corporate are included in the total operating EBITDA margin %s above.

Depreciation and Amortization (Pretax)

<i>In millions</i>	YTD 2025	3Q25	2Q25	1Q25	FY 2024	4Q24	3Q24	2Q24	1Q24
Healthcare & Water Technologies	\$ 278	\$ 93	\$ 93	\$ 92	\$ 352	\$ 92	\$ 90	\$ 87	\$ 83
Diversified Industrials	181	60	62	59	245	62	62	61	60
Corporate ¹	29	9	11	9	38	9	11	10	8
Total depreciation and amortization by segment (Pretax)	\$ 488	\$ 162	\$ 166	\$ 160	\$ 635	\$ 163	\$ 163	\$ 158	\$ 151

1. Corporate primarily reflects impacts of previously divested businesses.

Equity Earnings

<i>In millions</i>	YTD 2025	3Q25	2Q25	1Q25	FY 2024	4Q24	3Q24	2Q24	1Q24
Healthcare & Water Technologies	\$ 1	\$ 1	\$ -	\$ -	\$ 1	\$ 1	\$ (1)	\$ -	\$ 1
Diversified Industrials	-	-	-	-	1	-	-	1	-
Corporate	(7)	(1)	9	(15)	(8)	(1)	(2)	1	(6)
Total equity earnings included in operating EBITDA (non-GAAP)	\$ (6)	\$ -	\$ 9	\$ (15)	\$ (6)	\$ -	\$ (3)	\$ 2	\$ (5)